PUBLICATIONS & PRESENTATIONS
INVESTORS & MEDIA
Positive Top-Line Data from Phase IIb Study Evaluating TLPLDC
Elios Therapeutics Announces Appointment of Phillip Johnson as Chief Financial Officer
Perseus Holdings USA Appoints Veteran Biotechnology Executive William C. Pearson to BOD
Interim Phase IIb Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine
Initial Phase 2b Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine...
We would love to hear from you. Tell us a little about yourself and we will reach out.
Thanks for your message!
Elios Therapeutics, LLC 5900 Southwest Parkway, Building 2, Suite 220
Austin, TX 78735